ATE265204T1 - Micropartikeln zur verwendung in nadellosen injektion - Google Patents

Micropartikeln zur verwendung in nadellosen injektion

Info

Publication number
ATE265204T1
ATE265204T1 AT99943130T AT99943130T ATE265204T1 AT E265204 T1 ATE265204 T1 AT E265204T1 AT 99943130 T AT99943130 T AT 99943130T AT 99943130 T AT99943130 T AT 99943130T AT E265204 T1 ATE265204 T1 AT E265204T1
Authority
AT
Austria
Prior art keywords
microparticles
needleless injection
therapeutic agent
agent
spray
Prior art date
Application number
AT99943130T
Other languages
English (en)
Inventor
Nicholas David Osborne
Original Assignee
Quadrant Drug Delivery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10838317&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE265204(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Quadrant Drug Delivery Ltd filed Critical Quadrant Drug Delivery Ltd
Application granted granted Critical
Publication of ATE265204T1 publication Critical patent/ATE265204T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Disintegrating Or Milling (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Glanulating (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT99943130T 1998-09-03 1999-09-03 Micropartikeln zur verwendung in nadellosen injektion ATE265204T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9819272.7A GB9819272D0 (en) 1998-09-03 1998-09-03 Microparticles
PCT/GB1999/002930 WO2000013668A1 (en) 1998-09-03 1999-09-03 Microparticles

Publications (1)

Publication Number Publication Date
ATE265204T1 true ATE265204T1 (de) 2004-05-15

Family

ID=10838317

Family Applications (2)

Application Number Title Priority Date Filing Date
AT04075082T ATE386507T1 (de) 1998-09-03 1999-09-03 Mikropartikel
AT99943130T ATE265204T1 (de) 1998-09-03 1999-09-03 Micropartikeln zur verwendung in nadellosen injektion

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT04075082T ATE386507T1 (de) 1998-09-03 1999-09-03 Mikropartikel

Country Status (15)

Country Link
US (3) US20020197325A1 (de)
EP (2) EP1410792B1 (de)
JP (2) JP2002524411A (de)
CN (1) CN1315854A (de)
AT (2) ATE386507T1 (de)
AU (1) AU5640799A (de)
BR (1) BR9913456A (de)
CA (1) CA2342206C (de)
DE (2) DE69938201T2 (de)
DK (1) DK1107737T3 (de)
ES (2) ES2301929T3 (de)
GB (1) GB9819272D0 (de)
IL (1) IL141323A0 (de)
MX (1) MXPA01002323A (de)
WO (1) WO2000013668A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002538195A (ja) * 1999-03-08 2002-11-12 パウダージェクト リサーチ リミテッド 生物活性化合物の持続放出用の無針注射器を使用する微粒子製剤の送達
US8771740B2 (en) * 1999-12-20 2014-07-08 Nicholas J. Kerkhof Process for producing nanoparticles by spray drying
DE10045521A1 (de) 2000-03-31 2001-10-04 Roche Diagnostics Gmbh Nukleinsäureamplifikationen
US7575761B2 (en) 2000-06-30 2009-08-18 Novartis Pharma Ag Spray drying process control of drying kinetics
US20030152637A1 (en) * 2001-01-25 2003-08-14 Mark Chasin Local anesthetic, and method of use
EP1399132A1 (de) * 2001-06-08 2004-03-24 Powderject Vaccines, Inc. Herstellung von harten und dichten partikeln
EP1992335A1 (de) 2001-11-01 2008-11-19 Nektar Therapeutics Sprühtrocknungsverfahren und Zusammensetzungen dafür
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
WO2005009375A2 (en) * 2003-07-22 2005-02-03 Baxter International Inc. Small spherical particles of low molecular weight organic molecules and methods of preparation and use thereof
JP4210231B2 (ja) * 2004-03-25 2009-01-14 株式会社資生堂 皮膚のシワを改善する美容方法及びシワ改善具
US8728525B2 (en) 2004-05-12 2014-05-20 Baxter International Inc. Protein microspheres retaining pharmacokinetic and pharmacodynamic properties
EP1863451A2 (de) * 2005-03-31 2007-12-12 Rafael-Armament Development Authority Ltd. Sphärisch geformte substanzen
EP1912730A2 (de) * 2005-07-28 2008-04-23 Isp Investments Inc. Verfahren zur verbesserung der eigenschaften von sprühgetrockneten pulvern und granulierten materialien und danach erhaltene produkte
EP1976486A1 (de) * 2006-01-27 2008-10-08 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Verfahren zur herstellung von porösen mikroteilchen
AU2007281737B2 (en) 2006-08-04 2013-09-19 Baxter Healthcare S.A. Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes
DE202006018609U1 (de) * 2006-08-29 2007-05-16 Euro-Celtique S.A. Verwendung von Opioidformulierungen in nadellosen Vorrichtungen zur Medikamentenverabreichung
US20080085315A1 (en) * 2006-10-10 2008-04-10 John Alfred Doney Amorphous ezetimibe and the production thereof
WO2008076780A2 (en) * 2006-12-14 2008-06-26 Isp Investments Inc. Amorphous valsartan and the production thereof
WO2008080037A2 (en) * 2006-12-21 2008-07-03 Isp Investments Inc. Carotenoids of enhanced bioavailability
JP5508859B2 (ja) * 2007-01-26 2014-06-04 アイエスピー インヴェストメンツ インコーポレイテッド 噴霧乾燥製品を製造するための調剤処理方法
ITMI20080807A1 (it) 2008-05-05 2009-11-06 Antibioticos Spa Procedimento per la preparazione di tigeciclina in forma amorfa
US8323685B2 (en) 2008-08-20 2012-12-04 Baxter International Inc. Methods of processing compositions containing microparticles
US8323615B2 (en) 2008-08-20 2012-12-04 Baxter International Inc. Methods of processing multi-phasic dispersions
US8367427B2 (en) 2008-08-20 2013-02-05 Baxter International Inc. Methods of processing compositions containing microparticles
CN101732259B (zh) * 2009-12-29 2012-08-29 广东药学院 壳聚糖微米粒及其制备方法和应用
US9135998B2 (en) * 2010-11-09 2015-09-15 Micron Technology, Inc. Sense operation flags in a memory device
EP2898894A1 (de) 2014-01-27 2015-07-29 LTS LOHMANN Therapie-Systeme AG Nano-in-mikro-Teilchen zur intradermalen Verabreichung
US20200353127A1 (en) * 2018-01-10 2020-11-12 G2Gbio, Inc. Collagen peptide-containing polycaprolactone microsphere filler and preparation method therefor

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3937668A (en) * 1970-07-15 1976-02-10 Ilse Zolle Method for incorporating substances into protein microspheres
CA1077842A (en) * 1975-10-09 1980-05-20 Minnesota Mining And Manufacturing Company Albumin medicament carrier system
US4247406A (en) * 1979-04-23 1981-01-27 Widder Kenneth J Intravascularly-administrable, magnetically-localizable biodegradable carrier
US4349530A (en) * 1980-12-11 1982-09-14 The Ohio State University Implants, microbeads, microcapsules, preparation thereof and method of administering a biologically-active substance to an animal
US4357254A (en) * 1981-01-12 1982-11-02 Chemical Sciences, Inc. Cleaning composition
FR2505657A1 (fr) * 1981-05-13 1982-11-19 Pasteur Institut Perfectionnements apportes aux agents de stabilisation de virus vivants pour la preparation de vaccins, et vaccins stabilises contenant lesdits agents de stabilisation
US5707644A (en) * 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
FR2663224B1 (fr) * 1990-06-14 1995-01-20 Applicationes Farmaceuticas Sa Forme galenique parenterale.
AU669952B2 (en) * 1992-10-16 1996-06-27 Glaxo Group Limited Taste-masking compositions of ranitidine
TW404844B (en) * 1993-04-08 2000-09-11 Oxford Biosciences Ltd Needleless syringe
US5899880A (en) * 1994-04-08 1999-05-04 Powderject Research Limited Needleless syringe using supersonic gas flow for particle delivery
NZ288185A (en) * 1994-06-15 1998-02-26 Dumex Alpharma As Particulate pharmaceutical formulation containing coated cores comprising at least 80% of an inert carrier having a friability of <20%; the inert carrier can be calcium carbonate
IT1274879B (it) * 1994-08-03 1997-07-25 Saitec Srl Apparecchio e metodo per preparare forme farmaceutiche solide a rilascio controllato del principio attivo.
GB9502879D0 (en) * 1995-02-14 1995-04-05 Oxford Biosciences Ltd Particle delivery
KR100201352B1 (ko) * 1995-03-16 1999-06-15 성재갑 단일주사 백신 제형
US5922253A (en) * 1995-05-18 1999-07-13 Alkermes Controlled Therapeutics, Inc. Production scale method of forming microparticles
US6117449A (en) * 1996-03-22 2000-09-12 Bio-Sphere Technology, Inc. Method for inducing a systemic immune response to a hepatitis antigen
US5985309A (en) * 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
GB9612629D0 (en) * 1996-06-17 1996-08-21 Oxford Biosciences Ltd Method for providing dense particle compositions for use in transdermal particle delivery

Also Published As

Publication number Publication date
DE69938201D1 (de) 2008-04-03
WO2000013668A1 (en) 2000-03-16
EP1107737A1 (de) 2001-06-20
JP2002524411A (ja) 2002-08-06
CA2342206C (en) 2006-12-12
US20070026081A1 (en) 2007-02-01
ATE386507T1 (de) 2008-03-15
IL141323A0 (en) 2002-03-10
US20020197325A1 (en) 2002-12-26
BR9913456A (pt) 2001-07-24
EP1410792A1 (de) 2004-04-21
MXPA01002323A (es) 2002-05-08
EP1410792A8 (de) 2004-12-29
CA2342206A1 (en) 2000-03-16
DK1107737T3 (da) 2004-08-02
US20050002870A1 (en) 2005-01-06
JP2006096755A (ja) 2006-04-13
AU5640799A (en) 2000-03-27
EP1410792B1 (de) 2008-02-20
EP1107737B1 (de) 2004-04-28
ES2301929T3 (es) 2008-07-01
GB9819272D0 (en) 1998-10-28
DE69916856T2 (de) 2005-04-21
CN1315854A (zh) 2001-10-03
ES2223181T3 (es) 2005-02-16
DE69938201T2 (de) 2009-02-12
DE69916856D1 (de) 2004-06-03

Similar Documents

Publication Publication Date Title
DE69916856T2 (de) Micropartikeln zur verwendung in nadellosen injektion
CY1107351T1 (el) Καινοφανης μεταλλαγμενη μορφη απιμινασης αργινινης
WO1999014346A3 (en) SENSE mRNA THERAPY
MX9603925A (es) Combinaciones de anticoagulantes y proteinas activas tromboliticamente, y usos de las mismas.
NZ505408A (en) Magnetically responsive composition, comprising ferrocarbon and a biologically active substance
BR9910251A (pt) Estimulação hematopoiética
DE69113386D1 (de) Herstellung von Medikamenten zur Behandlung von Asthma, unter Verwendung von (S)-Alpha-Fluoromethyl-Histidin und dessen Estern.
SG144712A1 (en) Nordihydroguaiartic derivaties for use in treatment of tumors
ATE280496T1 (de) Verfahren zur behandlung von asthma mit o- desulfatisiertem heparin
NO961291L (no) Prosess II
ATE230618T1 (de) Fibrin-gewebekleber-formulierung und verfahren zu dessen herstellung
NO971341D0 (no) Promoter for reseptor tyrosinkinase TIE
DE50014532D1 (de) Verwendung von (+)-tramadol, o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol zur therapie der harninkontinenz
ATE433461T1 (de) Rana pipiens proteine und deren verwendung in der behandlung von tumoren
IT1295751B1 (it) Procedimento per la produzione di protesi dentali fisse in resina, inserti per le stesse e protesi fisse cosi&#39; ottenute
GEP20043267B (en) Adenosine Receptor Antagonists, Methods of Making and Using the Same
DE69821498D1 (de) Verwendung von amifostin
WO1998040498A3 (en) Immunoadhesins and methods of production and use thereof
ITRM930291A0 (it) Procedimento per la preparazione di biopolimeri iodurati con attivita&#39;disinfettante e cicatrizzante, e biopolimeri iodurati cosi&#39; ottenuti.
IL139616A0 (en) Recombinant (alpha)-l-iduronidase, methods for producing and purifying the same and methods for treating, diseases caused by deficiencies thereof
ATE271852T1 (de) Verbesserte inhalationspräparate
BG105204A (en) Salts of paroxetine
BR0000698A (pt) 15, 15&#39;-dioxigenases de beta, beta-caroteno
GB9929497D0 (en) Improved amino acid mixtures for the treatment and/or management of certain diseases
IL148980A0 (en) An antibody to human tissue factor and experimental animals having inserted cells with the gene encoding human tissue factor

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1107737

Country of ref document: EP